The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You just don’t understand. There is no good news imminent or Avacta would have held off the fund raise to carry it out at a higher SP. C7 adds little by way of proving efficacy and why should it it’s still about safety. And as far as we know arm 2 hasn’t started dosing yet.
Doggy
I don’t think any of us understand it.
Even though I have warned caution in the past, my main point was that it would take longer and the SP would not reach the dizzy heights ramped on here.
But I did not expect this. This surpasses the LFT shafting.
If arm 2 delivers the data then they may still get a good license deal. Fingers crossed
We would have to be mad to do a placing at this SP
Be suicide to do a placing now especially as we don’t need more funds yet
Bella
Or it could point to “nothing to present”☹️
John
I to you were giving yourself until the end of the week even though you can’t say why other than the SP making some sort of pattern
Icecool
TBH I believe AVA6000 has shown enough already to be a marked improvement on dox even if with current dosing regime it is just stopping disease progression . But I believe to be the success we all want and expect it to be it needs to show consistent tumour reduction across most if not all patients. I am expecting arm 2 data to show this unequivocally. Until then, in Dr Tap’s own words “ . . . encouraging. . potentially . . . encouraging “.
I clearly state that;
The platform works
AVA6000 is being cleaved predominantly at the tumour
I’m not sure about rate of cleaving fix versus excretion of AVA6000 from the body
One patient with a 65% reduction in tumour is amazing but not statistically significant
Ditto the small number of biopsies out of the total number of patients
Gen
Confess I haven’t been watching the Diagnostics side.
It would be brilliant if that came to pass👍
Oh and just to improve my popularity
Yes the platform works.
Yes AVA6000 is being cleaved
But I’m still not sure enough is being cleaved at the tumour before the bulk is excreted from the system. Hence 2 weekly doing INHO
Icecool
I’ve said when I expect the ongoing discussions to conclude and that is mid year. And most certainly they will have to be well underway now and no doubt are anticipating great arm 2 data.
Gen
Good point and it will help the balance sheet but I doubt the SP would reach the heights we need it to on that alone.
The likelihood is that the SP will continue to slide until arm 2 data published around mid year with perhaps a brief spike when C7 data released. Because there are signs of improvement elsewhere and folks can use their cash to invest in other companies and make money in the meantime. So why keep it in Avacta doing nothing.
And no amount of scaremongering by the cheerleaders that there is going to be a pivotal RNS tomorrow will change that.
More fantastic rumours
Watching
None of the trolls wish you harm. Why is it you are such a bitter and angry chap that you constantly want harm to come to us?
Icecool
I agree that most proble is a licence deal but not until incontrovertible data is published from arm 2 after mid year
Please tell me that the cheerleaders aren’t going to keep up this fantasising about c7 data or a takeover or a joint venture next week all the way through until mid year when we get arm 2 data and all is revealed.
Watching
A joint venture with whom?
Where did you get this info?
Strangy
Don’t you read any of the stuff that comes out of Avacta?
News is not imminent